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Novel artificial tissues with potential usefulness in local-based therapies have been generated by tissue 
engineering using magnetic-responsive nanoparticles (MNPs). In this study, we performed a comprehensive in 
vivo characterization of bio-engineered magnetic fibrin-agarose tissue-like biomaterials. First, in vitro analyses 
were performed and the cytocompatibility of MNPs was demonstrated. Then, bioartificial tissues were generated 
and subcutaneously implanted in Wistar rats and their biodistribution, biocompatibility and functionality were 
analyzed at the morphological, histological, hematological and biochemical levels as compared to injected MNPs. 
Magnetic Resonance Image (MRI), histology and magnetometry confirmed the presence of MNPs restricted to 
the grafting area after 12 weeks. Histologically, we found a local initial inflammatory response that decreased 
with time. Structural, ultrastructural, hematological and biochemical analyses of vital organs showed absence of 
damage or failure. This study demonstrated that the novel magnetic tissue-like biomaterials with improved 
biomechanical properties fulfill the biosafety and biocompatibility requirements for future clinical use and 
support the use of these biomaterials as an alternative delivery route for magnetic nanoparticles. 
 







During the last years, magnetic nanoparticles (MNPs) have been evaluated in biomedicine for hyperthermia 
induction [1], cell labeling and separation [2], DNA separation [3], magnetic resonance imaging [4] and for drug 
or gene therapies [5], [6]. Iron oxides MNPs are the most commonly used, especially Fe3O4 (magnetite) and 
ᵧFe2O3 (maghemite), because these are stable from a thermal, chemical and colloidal standpoint. In addition, 
based on the MNPs magnetic properties, it was hypothesized that these particles could be guided to specific in 
vivo locations using a magnetic field gradient. This could be useful as an alternative method to concentrate 
growth factors, drugs or cells associated to the particles [7], [8], [9], and it has been postulated that MNPs could 
be useful tools for theracnostic [10] and tissue engineering applications as a tool for local-based therapies [11], 
[12], [13], [14] [15]. MNPs were previously tested for the generation of bioengineered magnetic tissue-like 
substitutes with improved properties, without affecting cell adhesion, proliferation, viability or differentiation in 
vitro [16], [17], showing a significant improvement of the biomechanical properties of these biomaterials [11], 
[17]. 
Concerning in vivo biodistribution of MNPs, it is clear that the administration route will be a critical factor 
determining bioavailability and in vivo functionality of MNPs [10]. To date, several studied focused on 
determining the fate of these particles when injected into the bloodstream [10], and results demonstrated that 
injected MNPs have a short lifespan, tend to accumulate in different organs and may have certain degree of 
cytotoxic effects [10, 18]. However, the in vivo biodistribution when particles are applied immersed within a 
biomaterial needs further characterization [12], and in vivo studies evaluating the cellular and molecular 
processes related to biocompatibility, biodegradability and bio-distribution of implanted magnetic hydrogels are 
in need. Our group previously developed a fibrin-agarose hydrogel (FAH), which was successfully used in 
numerous tissue engineering applications [19], [20], [21], [22], [23], [24], [25] [26] and is currently used in 
clinical trials with the approval of the Spanish Agency of Medicines and Medical Devices (AEMPS) according 
to the EU guidelines for clinical use [27]. Therefore, FAH can be an useful carrier candidate to be combined with 
MNPs in order to generate novel biocompatible magnetic tissue-like biomaterials [11], [17], [13].  
The aim of this study was to determine the biocompatibility of FAH-based magnetic tissue-like biomaterials 
containing MagNP-OH magnetic nanoparticles and to study their in vivo biodistribution in a rat model. First, the 
structure and biocompatibility of magnetic hydrogels was determined in vitro. Then, magnetic scaffolds and 
scaffold-free MNPs were subcutaneously grafted and the host response was evaluated by magnetic resonance 
imaging, laboratory testing, histology and magnetometry after 12 weeks in vivo. 
 
2. Materials and methods 
2.1 In vitro analyses 
2.1.1 Magnetic nanoparticles (MNPs) characterization 
In this study, we used commercially available MNPs (Nanomyp, Granada, Spain) referred as MagNP-OH. These 
MNPs have a mean hydrodynamic diameter of 100-120 nm and are composed by a polycrystalline of magnetite 
core coated by methyl methacrylate-co-hydroxyl ethyl methacrylate-co-ethylene glycol dimethacrylate (MMA-
co-HEMA-co-EGDMA). The MagNP-OH particles were prepared for analyses following previously described 
procedures [11], [17].   
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The ultrastructure and dimension of the MagNP-OH were determined by using a LIBRA 120 PLUS Carl Zeiss 
transmission electron microscope (TEM). In addition, the magnetic properties of the MagNP-OH were 
characterized by vibrating sample magnetometer VSM 4500 (EG&G Princeton Applied Research, USA).  
 
2.1.2 Analysis of biocompatibility of the MagNP-OH on 2D cell cultures 
2.1.2.1 Cell culture and cell-MagNP-OH interaction model  
Human fibroblast primary cultures obtained from human oral mucosa biopsies were cultured in 24-well plates 
(2x104 cells/well) with Dulbecco’s Modified Eagle Medium (DMEM) with 10 % Fetal Bovine Serum (FBS) and 
antibiotics/antimycotics commercial cocktail solution (all from Sigma-Aldrich, Germany) at 37°C and 5% CO2 
during 24 h. MagNP-OH particles were added to cultured cells at a concentration of 0.5% and 1% (w/v) in 
DMEM (without FBS and antibiotics) and were kept in culture for 24 h, and biocompatibility was determined 
after this time. As positive controls of live cells (100% cell viability), the same cells were cultured without 
MagNP-OH particles. As negative controls (100% cytotoxicity), cells were incubated in the same medium with 
1% of Triton X-100. Biocompatibility was analyzed in six independent samples and viability was evaluated 4 
times in each sample (24 measures by condition and test).  
 
2.1.2.2 In vitro assessment of MagNP-OH cytocompatibility 
Cytocompatibility was evaluated using a combination of morphological analyses, functional WST-1 cell 
viability/proliferation assay and quantification of free DNA released from dead cells (able to detect cell 
membrane structural integrity), as previously described [20], [28], [29]. First, the morphological changes 
associated to the presence of MagNP-OH were determined by phase contrast microscopy. Then, we analyzed the 
metabolic activity of the human cells using commercially available WST-1 assays (Roche Diagnostic, 
Mannheim, Germany) using a Microplate Reader (Biochrom® Asys UVM340) at a wavelength of 450–690 nm 
[20], [28]. Finally, the DNA-released as a consequence of irreversible cell membrane damage was quantified by 
using a NanoDrop 2000 UV-vis spectrophotometer (Thermo Fisher Scientific) [12], [20].  
 
2.1.2.3 Preparation of the magnetic tissue-like biomaterials  
In this study, we prepared three types of scaffolds: non-magnetic FAH, and two types of magnetic FAH: FAH 
containing MagNP-OH (FAH-MNPs), and FAH containing MagNP-OH with the application of a definite 
magnetic field during gelation (FAH-MNPs-F). For the preparation of FAH and the magnetic scaffolds (FAH-
MNPs and FAH-MNPs-F), we used a variation of a previously described method for non-magnetic FAH [19], 
[22], [28], [30], [31]. Briefly, hydrogels were generated by mixing 70% of human plasma, 13.5% of PBS 
phosphate buffer (0.1M, pH 7.2-7.4) containing or not MagNP-OH (0.5% v/v of final hydrogel volume) and 
1.5% of tranexamic acid. This solution was carefully mixed and then, a 2% solution of CaCl2 was added (10% of 
the final volume) to promote fibrin gelation, followed by a 5% volume of melted 2% type VII agarose in PBS. 
This mixture was aliquoted and kept in a cell incubator using standard culture conditions until complete gelation 
[11]. In the case of FAH-MNPs-F, the mixture was subjected to a vertical magnetic field (48 kA/m) during the 
first 5 minutes of the process of jellification in order to obtain an anisotropic biomaterial composed by aligned 





2.1.2.4 Analysis of biomechanical properties of the magnetic tissue-like biomaterials 
Magnetic and non-magnetic tissue-like biomaterials were subjected to oscillatory shear strains of increasing 
amplitude and fixed frequency (1 Hz) and the corresponding oscillatory shear stress was assessed using a Haake 
MARS III (Thermo Fisher Scientific, Waltham, MA, USA) controlled stress rheometer at 37°C. The measuring 
system geometry was a 3.5 cm diameter parallel plate set with rough surfaces to avoid wall slip, and the rotating 
plate was adjusted to a normal force of 5 N. Measurements were conducted under oscillatory shear strains and 
the biomechanical properties of the different tissue-like biomaterials were studied by determining the complex 
viscoelastic modulus of each sample. 
 
2.2 In vivo analyses 
2.2.1 Laboratory animals 
In this study, a total of eighty-five 12 week-old adult male Wistar rats weighing 250–300 g were used. Animals 
were maintained in the Experimental Unit of the University Hospital Virgen de las Nieves in Granada (Spain). 
Animals were housed in a temperature-controlled room (21 ± 1°C) on a 12 h light/dark cycle with ad libitum 
access to tap water and standard rat chow. These studies were performed according to the European Union and 
Spanish Government guidelines for the ethical care of animals (EU Directive No. 63/2010, RD 53/2013) and this 
project was approved by the CEEA ethical committee for animal experimentation (approval number: 03-7-15-
311). 
 
2.2.2 Surgical procedure and experimental groups 
For the in vivo biocompatibility evaluation of magnetic tissue-like biomaterials, and to study the biodistribution 
of the MagNP-OH, animals were deeply anaesthetized by intraperitoneal injection of a mixture of acepromizine 
(Calmo-Neosan®, 0.001 mg/g of weight of the animal) and ketamine (Imalgene 1000®, 0.15 mg/g of weight of 
the animal). Each animal was randomly assigned to one of the following experimental groups (n=20 in each 
except for the control group):  
- (i) FAH group: once anesthetized, a 1cm-long incision of was made in the forearm skin of each animal, 
a FAH tissue-like substitute was subcutaneously grafted, and the injury was repaired using absorbable 
sutures. These animals were used as a control group (no MNPs).  
- (ii) FAH-MNPs group: in these animals, FAH containing 0.5% (v/v) MagNP-OH were implanted 
following the same procedure described for the FAH group. 
- (iii) FAH-MNPs-F group: FAH containing 0.5% (v/v) MagNP-OH subjected to magnetic field during 
gelation were implanted. 
- (iv) MNPs-INJ group: in this case, MNPs were implanted in the same area of groups i, ii and iii 
(forearm subcutaneous tissue), but particles were injected in this case. With this purpose, a 
subcutaneous injection of MNPs was given in both forearms of each rat (250 µl of a sterile 
physiological solution containing 12.5 mg of MagNP-OH).  
- (v) CTR group: five healthy animals were used as controls.  
Animals were euthanized after 1, 3, 5 or 12 weeks (n= 5 in each) by using an overdose of anesthetics followed 





2.2.3 Magnetic resonance imaging (MRI) 
Magnetic Resonance Image (MRI) analysis was used to identify the grafted materials in each animal and to 
assess the effects of these materials on the morphology of some major body organs. For this purpose, 3 animals 
corresponding to each group (CTR, FAH, FAH-MNPs, FAH-MNPs-F and MNPs-INJ) were analyzed 12 weeks 
after the surgical procedure using a Biospec TM 70/20 USR device equipped with 7 Tesla Ultrashield 
Refrigerated magnets (Bruker, Germany). First, animals were anesthetized using isoflurane anesthetics and 
immobilized in a cradle designed for the analysis of laboratory rats. Then, a whole-body scan was performed on 
each animal, and the morphology of liver, kidneys, lymph nodes and spleen was evaluated. Then, the grafting 
site was specifically analyzed to determine the MRI morphology of the implant site and possible migration of the 
particles to local and regional tissues. 
 
2.2.3 Hematological and biochemical studies 
1.5 mL of blood were collected from 5 animals corresponding to 1, 3, 5 and 12 weeks of in vivo follow-up. 
Blood was stored in Eppendorf tubes containing 5% heparin.  For complete blood count, a Sysmex KX-21N 
automatic analyzer (Roche, Florida, USA) was used as recently described [32], to determine the following 
hematological parameters: concentration of hemoglobin (HGB), erythrocytes count (RCB), hematocrit count 
(HCT), platelets (PLT), white blood cells (WBC), lymphocytes (LYM), neutrophils (NEUT), monocytes-
basophils-eosinophils (MXD).  
For biochemical tests, blood was centrifuged for 15 min at 3,500 rpm and the supernatant serum was collected 
for analysis using a clinical chemistry analyzer Cobas c311 (Roche Laboratories, Florida, USA). The following 
biochemical parameters were analyzed in each sample: Alanine aminotransferase (ALT), urea (UREA), 
creatinine (CREJ2), iron (IRON2) (all RTU kits from Roche Laboratories) [32]. 
 
2.2.4 Histological and histochemical studies 
For the histological analyses, animals were deeply anesthetized and perfused with 4% neutral buffered 
paraformaldehyde. For all animals included in the study, the area of the implant (FAH, FAH-MNPs, FAH-
MNPs-F and MNPs-INJ) was carefully dissected and postfixed in 4% neutral buffered formaldehyde for 24 h, 
dehydrated and embedded in paraffin. For animals corresponding to 1 and 12 weeks of follow-up, four vital 
organs (liver, kidneys, lymph nodes and spleen) were also extracted, postfixed and embedded in paraffin. Tissue 
blocks were sectioned at 5 µm of thickness, rehydrated and stained with hematoxylin-eosin (H&E) for 
histological evaluation. In addition, different histochemical techniques were used to determine tissue-specific 
normal parameters. The periodic acid-Schiff histochemical method (PAS) was used to evaluate the glycogen 
content of the liver, the glomerular basement membrane of the kidney and the basement membranes of each 
tissue and organ. To identify the presence of ferric iron, all tissues and organs were stained with Perls (Prussian 
blue reaction) histochemical method contrasted with H&E as described previously [12].  
The percentage of positive area for Perls-positive histochemical reaction in the spleen was determined with 
ImageJ software (National Institutes of Health, USA) from each group at 1 and 12 weeks following a previously 
described methodology [28, 33]. 
 
 
2.2.5 Ultrastructural analyses 
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For the ultrastructural analyses, tissue samples corresponding to the 12 weeks follow-up period were obtained 
from each animal included in the in vivo study at the moment of the euthanasia. Samples were fixed in 2.5% 
glutaraldehyde, washed three times in cacodylate buffer and post-fixed in 1% osmium tetroxide. Tissues were 
then dehydrated and embedded in Epoxy resin, and sectioned. Ultrathin sections were stained with aqueous 
uranyl acetate and lead citrate, mounted on grids and analyzed in a Carl Zeiss EM902 transmission electron 
microscope (Carl Zeiss Meditec, Inc., Oberkochen, Germany). The presence of iron atoms in tissues was 
identified by Electron Energy-Loss Spectroscopy (EELS). 
 
2.2.6 Magnetometry 
After the euthanasia, we tracked the presence of particles at the site of implantation and vital organs. We 
checked the magnetic response of the samples with a neodymium magnet in a magnetic field gradient of 10 
mT/mm and a maximum field of 470 mT. In addition, we quantified the magnetic response of the samples by 
means of magnetometry measurements using a vibrating sample magnetometer VSM 4500 (EG&G Princeton 
Applied Research, USA) at room temperature. For this, similar volumes of tissue (equivalent to 50 mg of mass) 
were used from each condition. The detection limit of the magnetometer was 0.001 emu/g, which corresponds to 
approximately 30 µg of particles. These analyses were performed in animals corresponding to 12 weeks of in 
vivo follow-up. 
 
2.2.7 Statistical analyses 
In this study, all variables were subjected to Shapiro-Wilk test of normality and resulted to be non-normally 
distributed. Therefore, Fisher Exact Test and Mann-Whitney U test were used to determine statistical differences 
between comparison groups. All variables were analyzed by using the software SPSS 16.00 and results were 
shown as mean ± standard deviation (SD). In this study, p<0.05 was considered as statistically significant in two-
tailed tests. 
 
3. Results and Discussion 
3.1 In vitro characterization and biocompatibility 
First, our ultrastructural analysis of the MagNP-OH used in this study showed allowed us to confirm that the 
average diameter of these nanoparticles was 100-120 nm, size that is considerably higher than other single 
domain MNPs frequently used by other authors in tissue engineering (30-40 nm) [15], [16], [34], [35], [36], [37]. 
Interestingly, particles tended to form polycrystalline aggregates externally coated by a polymeric matrix 
surrounding each aggregate (Figure 1A). Magnetic characterization of the MagNP-OH revealed the typical soft 
ferromagnetic character of these MNPs, with negligible remnant magnetization, and a saturation magnetization 
of 161±7 kA/m (Figure 1B). It is well known that the size of the MNPs is directly related to the magnetic 
response of the particles, and multidomain MNPs (> 50 nm) commonly show higher magnetic response as 
compared to small particles [38]. Therefore, the polycrystalline aggregates generated in the present work may 
have the added value of having improved properties for use in tissue engineering [11], [17], [12]. 
Regarding in vitro cytocompatibility of human cells cultured in the presence of MagNP-OH, we carried out a 
combinate analysis at three levels: cell morphology, cell function and integrity of the cell membrane. Results 
show that, in general, these MNPs are highly cytocompatible. In the first place, co-culture of these MNPs with 
human cells was not able to modify the typical elongated spindle-like shape of viable human fibroblasts, 
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suggesting that these cells remained highly viable, and MNPs were mostly found homogeneously distributed in 
the extracellular space of the cells (Fig. 1C). In fact, morphology of these cells was comparable to positive 
control cells cultured without MNPs and very differernt to the small, rounded-shape appearance of negative 
control dead cells. To confirm these results at the functional level, we then analyzed the functionality of the 
cellular mitochondrial dehydrogenase by WST-1 assay. Results showed high levels of metabolic activity in cells 
containing MagNP-OH (at the concentration of 1% and 0.5%) with values comparable (p>0.05) to the positive 
control group. Positive controls and both experimental groups containing MagNP-OH showed significantly 
higher WST-1 values as compared to the negative control group (p<0.0001) (Figure 1D), suggesting high 
metabolic activity [20, 28]. Finally, viability was analized at the structural level by quantifying released DNA 
from cells cultivated in the presence of the MagNP-OH (Figure 1E), which is unfailingly associated to a cell 
membrane disruption [20, 28]. Results showed low cell mortality in positive controls and in both experimental 
groups (1% and 0.5%), with no differences between positive controls and cells cultured with MagNP-OH 
(p>0.05). However, mortality was significantly higher in negative controls (p=0.0020). These results are in 
agreement with the high cytocompatibility previously observed in hydrogels containing MagNP-OH [17], 
especially when these particles were coated with a polimer such as polyethylene glycol (PEG) [12]. The 
polymeric coating of MNPs provides hidrophilic properties that may improve stabilization in coloidal suspension 
and increase biocompatibility [10], [39]. Alltogether, these results support the high in vitro biocompatibility of 
the coated MagNP-OH used in this study. 
Once the cytocompatibility of MagNP-OH was evaluated in vitro, we generated magnetic tissue-like 
biomaterials containing these particles. The rheological characterization of FAH-MNPs and FAH-MNPs-F 
revealed that incorporation of MagNP-OH considerably increased the strength of the tissue-like biomaterials as 
compared to control nonmagnetic FAH for the complex viscoelastic modulus ( ) ( )  2122 '''* GGG +=  (Figure 
1F), for both the biomaterials subjected to magnetic fields during the polymerization and materials devoid of 
these fields. These findings are in agreement with our previous studies showing that MNPs can considerably 
improve the biomechanical properties of FAH, thus increasing their putative usefulness in tissue engineering and 





Figure 1. In vitro characterization of the MagNP-OH particles used in this study. A) Transmission electron 
microscopy ultrastructural analysis of MagNP-OH particles. Scale bar: 200 nm (left) and 100 nm (right). B) 
Magnetization curve of MagNP-OH particles. C) Phase contrast microscopy image of gingival human fibroblasts 
culturee with MagNP-OH particles. Cells are labeled with black arrows and MagNP-OH particles are highlighted 
with white arrows. D) Results of the cellular metabolic activity as determined by WST-1 assay. E) Analysis of 
cell membrane integrity as determined by DNA quantification. In D and E, values correspond to averages and 
standard deviations.* Results are statistically different to all the other study groups. PC: positive controls; NC: 
negative controls. F) Biomechanical properties are shown as the complex viscoelastic modulus of nonmagnetic 
FAH, FAH-MNPs and FAH-MNPs-F. 
 
3.2 In vivo evaluation 
An accurate monitoring and analysis of the fate of MNPs grafted in vivo in laboratory animals is essential for 
their future clinical translation and practical application [40]. Ideally, biocompatibility of grafted MNPs should 
be assessed by using a combination of invasive and non-invasive methods allowing a precise evaluation of the 
fate of the MNPs and the potential metabolic pathways and organs involved in MNPs metabolism and 
biodegradation. Consequently, animals grafted with the different materials used were subjected to an array of 
highly accurate evaluation methods that included MRI, magnetometry, hematological, biochemical and 
histological analyses in order to determine biocompatibility and the outcome of the grafted materials. In addition, 
analyses were performed at the local and the distal level as requested by most National Medicines Agencies for 
Advanced Therapies Medicinal Products [41]. In this sense, we first analyzed the local graft site in order to 
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determine in situ biosafety, temporal stability and migration to neighbor tissues. Then, we analyzed four key 
distal organs to shed light on the possible distal effects of the grafted biomaterials, including distal organ 
migration. In general, all these analyses allowed us to demonstrate that the biomaterials used in the present work 
are safe and comply with the main biosafety requirement for future clinical use. 
In situ analysis of the implant site using MRI (Fig. 2) showed that non-magnetic FAH remained at the grafting 
site and were locally metabolized and reabsorbed in 12 weeks. In contrast, magnetic biomaterials containing 
MagNP-OH, as well as the injected MagNP-OH remained located in the implant site after 12 weeks of in vivo 
follow-up. These results coincide with the magnetometric analyses showing that controls and animals grafted 
with FAH were negative, whereas all animals with grafted MagNP-OH showed a highly positive magnetic 
response at the grafting site after 12 weeks of follow-up.  
 
 
Figure 2. Magnetic Resonance Images (MRI) analysis of animals with the different materials grafted in 
vivo for 12 weeks. Images were taken at the grafting site (top panel) and distal organs (lower panel). Red 
arrows: satellite lymph nodes; yellow arrows: kidneys; L: liver; white circles: hyperintense areas corresponding 
to MagNP-OH accumulation at the implantation site; white rectangle: spleen. CTR: control animals; FAH: 
fibrin-agarose hydrogels; FAH-MNPs: FAH containing MagNP-OH; FAH-MNPs-F: FAH containing MagNP-
OH subjected to magnetic field during gelation; MNPs-INJ: MNPs injected subcutaneously. 
 
Then, the implantation site was analyzed histologically. In this regard, most animals showed an initial mild local 
inflammatory reaction restricted to the tissues surrounding the implanted materials, but no signs of necrosis, 
infection, rejection or malignization were found in any of the groups (Fig. 3). This reaction was similar in all 
groups grafted with biomaterials (FAH, FAH-MNPs and FAH-MNPs-F), and tended to decrease over the time. 
In FAH group, it was found that the number of inflammatory cells, especially macrophages, decreased with time 
and almost disappeared after 12 weeks. An interesting finding of our study was that the three groups in which 
MNPs were grafted tended to encapsulate the grafts, with the formation of a central Perls-positive nucleus 
surrounded by a connective tissue capsule. Although we found a single nucleus in the FAH-MNPs and FAH-
MNPs-F groups, particles tended to form several independent nuclei in the MNPs-INJ group, at least during the 
first 5 weeks (Figure 3). These results confirm the absence of an increased inflammatory reaction driven by the 
MNPs implant and point out the usefulness of the FAH-MNPs model as a straightforward way of providing the 
host tissue with MNPs that could exert a positive clinical effect [42] [43]. As compared to injection, surgical 
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implantation of a tissue-like magnetic material allows a more efficient control of the grafting site and, according 
to our results, favor the MNPs containment and enhances encapsulation of the whole grafted mass in a single 
nucleus, thus preventing the connective tissue infiltration and grafts disaggregation or dispersion found in the 
MNPs-INJ group. In addition, the MNPs corresponding to the FAH-MNPs-F group showed a clear definite 
alignment and orientation of the MNPs during the first weeks, even though this orientation was lost after 5 weeks. 
Three-dimensional orientation of biomaterials is one of the goals of current tissue engineering, since most human 
tissues are characterized by a nonlinear and anisotropic mechanical behavior [44] due to the non-random 
distribution of its components, and this distribution is essential for its proper in vivo function. The use of FAH-
MNPs-F could contribute to obtain MNPs-based bioartificial tissues with defined alignment with added value for 




Figure 3. Perls histochemical results of grafted biomaterials and injected MNPs at 1, 3, 5 and 12 weeks in 
vivo. CTR: control animals; FAH: fibrin-agarose hydrogels; FAH-MNPs: FAH containing MagNP-OH; FAH-
MNPs-F: FAH containing MagNP-OH subjected to magnetic field during gelation; MNPs-INJ: MNPs injected 




Figure 4. Representative images corresponding to the ultrastructural analysis of materials grafted in vivo 
for 12 weeks. CTR: control animals; FAH: fibrin-agarose hydrogels; FAH-MNPs: FAH containing MagNP-OH; 
MNPs-INJ: MNPs injected subcutaneously. Black arrow phagosome with agarose and white arrow MNPs. Scale 
bars: 300µm (large images) and 20µm (inserts).  
 
Furthermore, we carried out TEM analyses to determine the biocompatibility of each biomaterial at the 
ultrastructural level after 12 weeks of the surgical procedure. On the one hand, host tissues corresponding to the 
FAH group showed macrophages with intracellular phagosomes containing rests of the biomaterial, along with 
extracellular matrix mainly consisting of collagen fibers similar to control tissues (Fig. 4). On the other hand, 
animals grafted with MNPs showed very similar behavior regardless of the specific group considered (FAH-
MNPs, FAH-MNPs-F and MNPs-INJ). In all these groups, we found numerous host cells compatible with 
macrophages containing abundant intracellular MNPs that tended to keep their original polycrystalline aggregate 
pattern inside the cells. Most of the particles gathered in cytoplasmic vesicles that could correspond to 
endosomes or secondary lysosomes, as well as large phagosomes. MagNP-OH were also found in the 
extracellular space. No signs of necrosis or cell alterations were detected in any of the study groups. These 
findings confirm the high biocompatibility of the different materials used in this study. In agreement with 
previous reports, our results suggest that iron oxide nanoparticles are mostly engulfed within the human cells and 
do not cause any detectable alterations in these cells [10, 46] 
Once the local implant site was analyzed, we evaluated the morphology, structure and function of several major 
distal organs of each animal to determine the possible distal effects of each biomaterial as part of the global 
biocompatibility and biosafety assessment required for future clinical use [41]. In this regard, the whole-body 
MRI scan analysis of each animal and the specific analysis of four key organs playing a role in metabolizing and 
processing a biomaterial grafted in vivo -liver, kidneys, lymph nodes and spleen- revealed a perfectly normal 
morphology devoid of detectable alterations (Fig. 2). No MNPs were detected by MRI in any of these organs. 
Similarly, analysis of the different organs using magnetometry revealed a negative signal in all animals after 12 
weeks of in vivo follow-up. These results suggest that MagNP-OH stayed at the grafting site and did not tend to 
migrate, supporting again the excellent biocompatibility and stability of this type of MNPs. 
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At the histological level, the structural analysis of distal organs confirmed the absence of alterations during the 
whole study. Indeed, no signs of inflammation, fibrosis, necrosis or other detectable tissue alterations were 
observed in histological sections of liver, kidneys, lymph nodes and spleen stained with H&E in any of the 
groups (Supplementary Fig. S1). Similarly, PAS staining analysis (Supplementary Fig. S2) confirmed that the 
content of glycogen was normal in hepatocytes of all groups of animals, and the glomerular and non-glomerular 
basement membranes were also free from detectable alterations. These results are in agreement with previous 
studies demonstrating that this type of MNPs coated with different polymers can be safely used without 
significant histological alterations of vital organs [12], [47], whereas other types of particles were associated to 
histological lesions in liver and kidney [48].  
In order to identify any possible particle migration to distal organs, we also analyzed these organs using the Perls 
histochemical technique, which is specific for detection of iron in cells and tissues. Results showed very few or 
no particles in liver and kidney at 1 and 12 weeks, but a positive reaction was found in spleen and lymph nodes 
at both analyzed times (Fig. 5). These findings are in agreement with previous reports demonstrating that 
nanoparticles of different nature tend to be massively captured by cells of the mononuclear phagocyte system 
[49]. Hence, we found that lymph nodes were Perls-negative in CTR and FAH group, whereas animals with 
grafted MNPs (FAH-MNPs, FAH-MNPs-F and MNPs-INJ) showed small Perls-positive areas after 1 week, and 
moderate to intense Perls-positive areas after 12 weeks, especially in the case of the injected MNPs. Then, we 
analyzed both components of the rat spleen (the red and the white pulp), and we found that the staining area and 
intensity was higher in this organ than in the rest of organs. As expected, the red pulp of the spleen was very 
positive to the Perls method in all groups, including controls, but this reaction became significantly more intense 
after 12 weeks in FAH-MNPs, FAH-MNPs-F and MNPs-INJ groups (p<0.05). These findings are consistent 
with the primary function of the red pulp, which is related to filtering peripheral blood from antigens, foreign 
bodies and all kinds of substances that may arrive to the blood, blood iron turnover, as well as serving as a huge 
reservoir of monocytes [18]. The white pulp, however, was mostly negative for this staining technique, although 
the marginal zone (in which antigen-presenting cells, such as dendritic cells and macrophages exists) was 
positive at 12 weeks in FAH-MNPs, FAH-MNPs-F and MNPs-INJ groups. Quantification of the Perls-positive 
areas in the red pulp (Figure 6) demonstrated no significant differences among samples at 1 week (p>0.05), but a 
significant increase was found at 12 weeks in the FAH-MNPs and MNPs-INJ groups (p<0.05). In fact, the three 
groups in which MNPs were grafted in animals, showed significant differences vs. control at week 12 (p<0.05). 
These results were corroborated at the ultrastructural level by TEM analysis confirming the presence of 
macrophages containing electrodense iron-rich granular material identified as iron by EELS in all experimental 
groups (Fig. 6). In contrast with the macrophages observed within grafted biomaterials, in spleen these cells 
contained iron-rich granular intracytoplasmic vesicles, but polycrystalline aggregates were not detected. 
The presence of abundant cells containing iron in the spleen of all animal groups can be explained by the 
important role that the spleen plays in mechanical filtration of red blood cells and hemoglobin iron recycling and 
turnover [18]. The increase observed in animals in which MagNP-OH were grafted, strongly suggests that 
MNPS could progressively reach to the spleen through blood circulation, as other authors demonstrated by 
intraperitoneal injection of RITC-labeled MNPs [10], [50]. The fact that our magnetometry and MRI analyses 
were negative could probably be explained by the low concentration of MagNP-OH that reached the spleen, 
which was probably below than 30 µg, which is the minimum concentration required for detection by 
magnetometry and MRI. Another possibility is that MagNP-OH were progressively transformed into non-
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magnetic iron forms by host cells as previously suggested [47]. Interestingly, previous works showed that 
superparamagnetic iron-oxide NPs show identical distribution pattern when administered in vivo [51].  
In consequence, our histological results, in line with results published by other authors, highlight the relevance of 
the administration route and NPs size in the subsequent organic biodistribution [10], and confirm that MagNP-
OH tend to remain stable at the implant site, with some particles biodistributed to lymphoid organs, without 




Figure 5. Perls histochemical results of distal organs at 1 and 12 weeks. FAH: fibrin-agarose hydrogels; 
FAH-MNPs: FAH containing MagNP-OH; FAH-MNPs-F: FAH containing MagNP-OH subjected to magnetic 
field during gelation; MNPs-INJ: MNPs injected subcutaneously; CTR: control animals. Scale bar 100 µm 
 
Figure 6. Quantitative results of Perls positive histochemical reaction and EELS in the red pulp of the 
spleen in each group and control. The table on top shows the results of the quantification of the percentage of 
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area corresponding to Perls-positive signal. The figures below show illustrative ultrastructural images of 
macrophages containing iron in intracellular phagosomes corresponding to two groups of animals (FAH and 
FAH-MNPs), along with an EELS spectrum with a peak corresponding to intracellular iron. CTR: control 
animals; FAH: fibrin-agarose hydrogels; FAH-MNPs: FAH containing MagNP-OH; FAH-MNPs-F: FAH 
containing MagNP-OH subjected to magnetic field during gelation; MNPs-INJ: MNPs injected subcutaneously. 
Values in the table are shown as mean ± standard deviation for each group of animals and each follow-up time, 
and the statistical p values corresponding to the comparison of these values with CTR are shown in brackets. In 
the last row, the statistical p values corresponding to the comparison of values at 1 week vs. values at 12 weeks 
are shown for each study group. Significant differences (p<0.05) are highlighted with asterisks (*). Scale bar for 
FAH = 1µm and scale bar for FAH-MNPs = 2µm 
 
 
 HEMOGRAM  
 General count WBC/White cells  
 WBC (103) RBC (106) HGB HCT PLT (105) LYM MXD NEUT  
 µL-1 µL-1 g/dL % µL-1 % % %  
FAH 
3.04±1.51* 7.14±0.22* 13.5±0.52 39.54±1.1 5.16±1.99 45.68±23.56 32.56±22.96 21.76±4.64 1 W 
4.56±3.31 7.61±0.06 14.14±0.51 42.28±0.66 4.60±2.59 64.38±14.8 12.96±0.86 22.66±14.22 3 W 
2.75±0.26* 8.04±0.4 14.15±0.27 43.78±1.3 6.57±0.23 77.63±4.06 9.25±3.02 13.13±5.75 5 W 
9.74±3.89 8.15±0.38 14.32±0.2 44.06±1.93 5.11±3.63 68.5±16.18 9.32±3.65 22.18±13.58 12 W 
FAH-MNPs 
2.4±1.27 7.47±0.64 13.22±1.48 40.02±4.35 5.63±2.96 42.08±26.77 33.02±25.75 24.84±12.87 1 W 
5.18±3.11 7.51±0.3 14.16±0.76 42.26±2.17 3.82±2.16 62.02±15.52 13.34±2.57 24.64±16.25 3 W 
2.48±1.09 8.11±1.48* 14.18±9.93 44.27±1.72 6.24±2.57 72.7±16.81 5.92±1.78 21.08±9.9 5 W 
2.94±3.52 7.83±0.68 14.16±0.76 42.48±4.15 8.74±0.84 80.32±3.35* 15.28±4.59 2.56±5.96 12 W 
FAH-MNPs-F 
3.63±2.1 7.76±0.38 13.83±0.25 42.43±1.85 5.61±1.21 66.25±8.58 13.83±5.93 19.93±6.41 1 W 
2.46±0.46 7.62±0.44 13.58±0.39 41.18±1.69 6.31±0.72 76.02±3.35 11.04±1.35 12.94±2.11 3 W 
5.36±4.05 7.77±4.09* 13.91±0.6 42.73±1.81 3.62±2.48 68±12.91 16.02±7.07 15.98±6.97 5 W 
5.72±1.73 8.46±0.62* 14.52±0.6 45.66±3.1 3.78±4.1 69±13.41 12.64±2.97 18.36±11.6 12 W 
MNPs-INJ 
2.48±0.43 7.82±0.24 13.78±0.42 42.8±1.86 4.88±2.75 72.08±6.03 12.53±1.24 15.4±6.02 1 W 
1.92±0.64 7.54±0.26 13.5±0.24 41.22±1.51 6.26±0.73 73.2±7.71 14.92±5.72 11.88±2.58 3 W 
1.78±0.29 8.03±0.23* 14.08±0.83 43.94±2 5.94±2.82 74.5±3.71 10.82±4.98 14.68±6.67 5 W 
7.1±3.74 7.57±0.89 13.75±1.61 41.45±5.4 4.33±4.58 65.83±4.67 10.03±3.42 24.15±6.5 12 W 
CTR 5.93±3.46 7.72±0.11 13.9±0.5 42.25±1.07 2.58±2.71 63.03±15.39 14.33±6.75 22.65±13.16  
 
Table 1. Hematological profile. Summary of the mean and SD of parameters evaluated at 1, 3, 5 and 12 week. 
White blood cells (WBC), erythrocytes count (RBC), concentration of hemoglobin (HGB), hematocrit count 
(HCT), platelets (PLT), lymphocytes (LYM), monocytes-basophils-eosinophils (MXD), neutrophils (NEUT). 
Significant differences (p<0.05) between experimental and control groups are highlighted with asterisks (*). 
 
After the morphology and structure of local and distal tissues and organs were determined, we analyzed the 
effect of the different biomaterials on each animal group at the functional level. In this regard, hematological 
studies revealed that all parameters evaluated here were within the physiological range of normal values 
described in the literature for the Wistar rat (Table 1) [48]. However, some specific parameters showed 
significant differences with the control animals used in this study. In the case of the red blood cells (RBC), we 
observed a significant decrease of RBC counts in the FAH group at 1 week as compared to controls (p=0.009), 
which could be a consequence of the recent surgical procedure. In contrast, a significant increase of the number 
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of RBC was observed after 5 weeks in FAH-MNPs (p=0.016), FAH-MNPs-F (p=0.016) and MNPs-INJ 
(p=0.028), and also after 12 weeks for FAH-MNPs-F (p=0.028) as compared to controls. Interestingly, the 
increase of RBC values was not accompanied by significant variations of the concentration of hemoglobin 
(HGB) or hematocrit (HCT). The leukocytes (WBC) count showed a transient reduction in the FAH group at 5 
weeks as compared to controls (p=0.009), although the leukocyte formula was normal for all the study groups 
except for an increase of lymphocytes (LYM) at 12 weeks in FAH-MNPs group (p=0.010). Finally, the 
evaluation of platelets (PLT) showed an increase in all experimental groups over the time as compared to control 
animals. All these variations, which fell into the normal parameters of healthy Wistar rats [48], could be related 
to the host adaptive physiological response to the surgical procedure, healing process, active hydrogel 
biodegradation and MagNP-OH phagocytosis, being these results in line with the histological findings. A similar 
result was found for the biochemical parameters analyzed in plasma of each animals, which were normal in most 
cases (Table 2). First, the levels of circulating iron were similar to control animals at all study times (p>0.05). 
The lack of increase of circulating free iron supports the idea that MNPs remained stable and were not able to 
release a significant amount of iron to the circulation. Similarly, most hepatic function-related parameters fell 
within the physiological range of this species, except for an initial transient decrease of ALT in MNPs-INJ 
(p=0.028) that normalized thereafter. Finally, the two biochemical markers of renal function (urea and 
creatinine) were normal in all study groups. Additionally, the renal function-related parameters urea and 
creatinine (CREJ2) showed a transitory increase over the time in all experimental groups as compared to controls, 
which tended to normalize with time.  
Altogether, these hematological and biochemical results confirmed that the use of MagNP-OH is safe and in vivo 
implantation of these MNPs is not associated to a vital organ failure. Although some slight variations were found 
in specific groups of animals, values were in agreement with the physiological ranges described in the literature 
[48], and showed a clear normalization over the time. In addition, the normalization of blood and biochemical 
parameters is in line with the quantitative results observed in Wistar rats in which the sciatic nerve was repaired 
with acellular nerve grafts [32]. These findings confirm again that both administration routes for the MagNP-OH 
(injected or encapsulated) were safe for the host animal. In contrast, a previous study showed that the high-dose 
oral administration of other types of nanoparticles based on silver was related to hepatic and renal affection at 
the biochemical level, what clearly differed from our findings [48]. Finally, the hematological and biochemical 
profiles were in concordance with the histological and MRI results showing normal structure and morphology of 
distal organs, and. All this suggests that the in vivo injection and the subcutaneous implantation of the magnetic 
materials generated in this work was fully biocompatible and fulfilled the strict biosafety criteria required for 







Liver Kidney Other parameters 
 
 ALT CREJ2 UREA Fe  
 U/L mg/dl mg/dl µg/dl  
FAH 
46.28±10.26 0.75±0.08 42.32±6.71 162.27±0.29 1 w 
40.44±7.38 0.65±0.14 43.28±7.34 170.25±0.33 3 w 
41.35±17.39 0.6±0.24 38.08±13.76 164.214±0.61 5 w 
53.54±16.03 0.6±0.08 36.94±2.65 181.191±0.22 12 w 
FAH-MNPs 141±144.53 0.7±0.15 46.66±8.73 147.31±0.31 1 w 
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Table 2. Biochemical profile. Summary of the mean and SD of parameters evaluated at 1, 3, 5 and 12 week. 
Alanine aminotransferase (ALT), urea (UREA), creatinine (CREJ2) and iron (Fe). Significant differences 
(p<0.05) between experimental and control groups are highlighted with asterisks (*). 
 
In summary, these results suggest that MagNP-OH fulfill the biosafety and biocompatibility requirements for 
future clinical use. Incorporation of these MNPs in fibrin-agarose biomaterials allows the generation of novel 
biomaterials with improved biomechanical properties with guarantees of biosafety and biocompatibility 
demonstrated at the morphological, structural and functional levels. As an alternative route of delivery, tissue-
like biomaterials allow an efficient control of the MNPs biodistribution in vivo. Biodistribution analysis 
demonstrated that our strategy supports the local use of the MagNP-OH, which were mostly confined to the 
implantation area. In addition, tissue-like biomaterials based on fibrin-agarose combined with MagNP-OH 
allows easy handling and straightforward surgical implant of these nanoparticles, and facilitates local in vivo 
encapsulation of MagNP-OH as compared to injected MagNP-OH. In addition, the methodology described in the 
present manuscript also allowed the generation of novel biomaterials with a definite structural alignment using 
magnetic fields during gelation of the biomaterial. This could be advantageous for reproduction and treatment of 
human tissues requiring a specific 3D structural organization such as the human cornea [52], tendon [53] and 
cartilage [54] and also other tissues with an anisotropic behavior such as the human skin, nerve and oral mucosa 
and palate [55]. However, future clinical trials should demonstrate the usefulness of these tissue-like products. 
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Supplementary Figure S1. Histological analysis of four major distal organs using Hematoxylin and Eosin 
staining (H&E). FAH: fibrin-agarose hydrogels; FAH-MNPs: FAH containing MagNP-OH; FAH-MNPs-F: 
FAH containing MagNP-OH subjected to magnetic field during gelation; MNPs-INJ: MNPs injected 




Supplementary Figure S2. Histochemical analysis of four major distal organs using the PAS method. 
FAH: fibrin-agarose hydrogels; FAH-MNPs: FAH containing MagNP-OH; FAH-MNPs-F: FAH containing 
MagNP-OH subjected to magnetic field during gelation; MNPs-INJ: MNPs injected subcutaneously; CTR: 
control animals. Scale bar 100 µm 
 
